CBD for Individuals at Risk for Alzheimer's Disease

Eligibility Criteria

• 1. Must be between the ages of 55 - 85 and provide valid informed consent.
• 2. Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician.
• 3. Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently
• 4. Montreal Cognitive Assessment (MoCa) score is between 18-25
• 5. Participant must have a CDR score of .5 on the Clinical Dementia Rating scale (CDR), which includes an assessment of function and is often used to distinguish MCI from dementia.
• 6. Must have an informant that will be utilized over the course of the 24 week study (must be the same person throughout study)
• 7. Participant must pass a test of consent comprehension
• 8. Must be interested in using CBD to help with cognitive function
• 9. Must plan on living in the Denver metro area over the next 6 months
• 10. Able to attend in-person visits at the study site
• 1. Any other central nervous system (CNS) disease that would be expected to affect cognition, Parkinson's disease, multiple sclerosis.
• 2. Any history of brain injury (e.g., concussion with significant loss of consciousness)
• 3. Any significant systemic illness or unstable medical condition
• 4. Current use of Parkinson's medications, antipsychotic medications, anti-seizure medications, or anticholinergic medications
• 5. Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by the DSM-5-TR
• 6. Participation in other clinical studies involving neuropsychological measures being collected more than one time per year.
• 7. Reported use of other drugs (cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs of abuse at baseline.
• 8. Report using cannabis, including products with or without CBD, more than four times per month.
• 9. Recent history of, or meets criteria for major depression with suicidal ideation.
• 10. Reports use of medical CBD.
• 11. Liver function enzymes (AST, ALT) that are greater than 2x normal.
• 12. Currently taking medications known to be contraindicated with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate).
• 13. Pregnant at the time of study enrollment or unwilling to use contraception through the duration of the study (if not yet post-menopausal)
• 14. Individuals with potentially reversible causes of mild cognitive impairment (hypothyroidism, Vitamin B12 deficiency).